TMCI · XBRL financial data

Treace Medical Concepts financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TMCI's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	94,419	141,838	187,118	209,357	212,690
Cost of goods and services sold	17,826	27,523	35,181	41,093	42,938
Gross profit	76,593	114,315	151,937	168,264	169,752
Research and development	10,204	13,584	15,440	20,589	20,282
General and administrative	18,432	32,999	47,031	55,720	62,744
Total operating expenses	93,103	149,159	203,365	223,952	223,906
Other operating income (expense)	1	(403)	342	324	432
Operating income (loss)	(16,510)	(34,844)	(51,428)	(55,688)	(54,154)
Interest expense	4,060	4,398	5,167	5,256	5,320
Other income (expense)	(4,042)	(7,971)	1,901	(55)	(4,848)
Income tax expense (benefit)	0	0	0	0	0
Net income (loss)	(20,552)	(42,815)	(49,527)	(55,743)	(59,002)
Earnings per share, basic USD per share	(0.43)	(0.77)	(0.81)	(0.90)	(0.93)
Earnings per share, diluted USD per share	(0.43)	(0.77)	(0.81)	(0.90)	(0.93)
Weighted average shares, basic thousands of shares	48,416	55,277	60,852	62,112	63,269
Weighted average shares, diluted thousands of shares	48,416	55,277	60,852	62,112	63,269

Fiscal years (TMCI's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	105,833	19,473	12,982	11,350	10,708
Marketable securities	0	61,779	110,216	64,327	37,659
Accounts receivable	18,568	29,196	38,063	40,803	42,155
Inventory	10,561	19,330	29,245	39,255	36,031
Prepaid and other current assets	3,010	3,624	7,853	5,667	5,501
Total current assets	137,972	133,402	198,359	161,402	132,054
Property and equipment, net	2,849	15,338	22,298	25,953	29,752
Right-of-use asset	0	10,138	9,264	8,442	7,614
Goodwill	—	0	12,815	12,815	12,815
Total assets	140,821	159,024	251,907	217,094	190,581
Accounts payable	4,056	8,668	11,835	10,522	6,726
Accrued liabilities	4,518	6,216	10,458	7,197	5,784
Total current liabilities	18,210	30,245	45,033	34,925	30,635
Long-term debt	29,365	52,711	53,008	53,306	55,583
Lease liability, non-current	0	15,539	15,891	15,934	13,982
Total liabilities	47,748	98,495	113,969	104,202	103,249
Accumulated deficit	(41,905)	(84,720)	(134,247)	(189,990)	(248,992)
Total stockholders' equity	93,073	60,529	137,938	112,892	87,332
Total liabilities and equity	140,821	159,024	251,907	217,094	190,581
Common shares outstanding (cover page) thousands of shares	54,748	61,156	61,755	62,619	64,591

Fiscal years (TMCI's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(20,552)	(42,815)	(49,527)	(55,743)	(59,002)
Stock-based compensation	3,409	8,111	17,352	30,603	33,823
Depreciation and amortization	685	2,133	5,352	8,419	10,623
Net cash from operating activities	(17,193)	(30,648)	(34,575)	(37,167)	(15,970)
Purchases of property and equipment	2,705	14,838	11,458	11,593	13,517
Net cash from investing activities	(2,705)	(76,518)	(81,299)	35,375	13,251
Proceeds from long-term debt	0	0	—	—	—
Repayments of long-term debt	1,788	0	0	—	—
Net cash from financing activities	107,652	20,806	109,383	160	2,077
Net change in cash	87,754	(86,360)	(6,491)	(1,632)	(642)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Treace Medical Concepts	12,610	45,376	(4,698)*	65.0M	9.7 quarters	Q2 FY26 10-QJun 30, 2026
Bioventus	30,709	142,442	20,658*	not reported	—	Q3 FY26 10-QSep 26, 2026
SS Innovations International	13,647	not reported	(4,235)*	200.4M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
SANUWAVE Health	9,376	9,739	425*	8.6M	—	Q2 FY26 10-QJun 30, 2026
NeuroPace	12,538	22,826	(3,903)*	34.3M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Cerus	16,350	57,714	3,007*	202.0M	—	Q3 FY26 10-QSep 30, 2026
Electromed	20,450	19,417*	2,994*	8.4M	—	Q4 FY26 10-KJun 30, 2026
Tactile Systems Technology	75,110	91,858	11,978*	22.4M	—	Q3 FY26 10-QSep 30, 2026
Orasure Technologies	160,582	30,639	(9,921)*	69.0M	16.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.